Neuromyelitis optica spectrum disorders – specifics in children

Czech version

Authors: Z. Libá
Authors‘ workplace: Klinika dětské neurologie 2. LF UK a FN Motol, Praha
Published in: Cesk Slov Neurol N 2020; 83/116(supplementum 1): 68-71
doi: https://doi.org/10.14735/amcsnn2020S68

Overview

Neuromyelitis optica (NMO) and NMO spectrum disorders (NMOSD) are rare clinical conditions of relapsing inflammatory astrocytopathy and demyelination. NMO/NMOSD can occur at any age and endangers a patient with cumulating permanent disability. This paper focuses on specifics of NMO/NMOSD in children and regards current information about epidemiology, diagnostics, clinical course and treatment options. An early diagnosis and appropriate treatment of NMO/NMOSD increase a chance for better outcome in every patient, and especially in a child.

Keywords:

diagnostic criteria – children – neuromyelitis optica – diff erential diagnosis – treatment

Sources

1. Chitnis T, Ness J, Krupp L et al. Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. Neurology 2016; 86 (3): 245–252. doi: 10.1212/WNL.0000000000002283.

2. Tenembaum S, Chitnis T, Nakashima I et al. Neuromyelitis optica spectrum disorders in children and adolescents. Neurology 2016; 87 (9 Suppl 2): S59–S66. doi: 10.1212/WNL.0000000000002824.

3. Banwell B, Bar-Or A, Arnold DL et al. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol 2011; 10 (5): 436–445. doi: 10.1016/S1474-4422 (11) 70045-X.

4. Ketelslegers IA, Catsman-Berrevoets CE, Neuteboom RF et al. Incidence of acquired demyelinating syndromes of the CNS in Dutch children: a nationwide study. J Neurol 2012; 259 (9): 1929–1935. doi: 10.1007/s00415-012-6441-6.

5. Langer-Gould A, Zhang JL, Chung J et al. Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children. Neurology 2011; 77 (12): 1143–1148. doi: 10.1212/WNL.0b013e31822facdd.

6. Wingerchuk D, Banwell B, Bennett JL et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85 (2): 177–189. doi: 10.1212/WNL.0000000000001729.

7. Fryer JP, Lennon VA, Pittock SJ et al. AQP4 autoantibody assay performance in clinical laboratory service. Neurol Neuroimmunol Neuroinflamm 2014; 1 (1): e11. doi: 10.1212/NXI.0000000000000011.

8. Lechner C, Baumann M, Hennes EM et al. Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease. J Neurol Neurosurg Psychiatry 2016; 87 (8): 897–905. doi: 10.1136/jnnp-2015-311743.

9. Hennes EM, Baumann M, Schanda K et al. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology 2017; 89 (9): 900–908. doi: 10.1212/WNL.0000000000004312.

10. Borisow N, Mori M, Kuwabara S et al. Diagnosis and treatment of NMO spectrum disorder and MOG-ence-phalomyelitis. Front Neurol 2018; 9: 888. doi: 10.3389/fneur. 2018.00888.

11. Tenembaum S, Chitnis T, Ness J et al. Acute disseminated encephalomyelitis. Neurology 2007; 68 (16 Suppl 2): S23–S36. doi: 10.1212/01.wnl.0000259404.51352.7f.

12. Verhey LH, Branson HM, Makhija M et al. Magnetic resonance imaging features of the spinal cord in pediatric multiple sclerosis: a preliminary study. Neuroradiology 2010; 52 (12): 1153–1162. doi: 10.1007/s00234-010-0755-9.

13. Banwell B, Tenembaum S, Lennon VA et al. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology 2008; 70 (5): 344–352. doi: 10.1212/01.wnl.0000284600.80782.d5.

14. Deiva K, Absoud M, Hemingway C et al. Acute idiopathic transverse myelitis in children: early predictors of relapse and disability. Neurology 2015; 84 (4): 341–349. doi: 10.1212/WNL.0000000000001179.

15. Nohejlova H, Nytrova P, Liba Z. Akutní myelitida u dětí – soubor 20 dětí. Cesk Slov Neurol N 2018; 81/114 (2): 213–219. doi: 10.14735/amcsnn2018213.

16. Tavasoli A, Tabrizi A. Acute Transverse myelitis in children, literature review. Iran J Child Neurol 2018; 12 (2): 7–16.

17. Yeh EA, Graves JS, Benson LA et al. Pediatric optic neuritis. Neurology 2016; 87 (9 Suppl 2): S53–S58. doi: 10.1212/WNL.0000000000002822.

18. Absoud M, Cummins C, Desai N et al. Childhood optic neuritis clinical features and outcome. Arch Dis Child 2011; 96 (9): 860–862. doi: 10.1136/adc.2009.175422.

19. McKeon A, Lennon VA, Lotze T et al. CNS aquaporin-4 autoimmunity in children. Neurology 2008; 71 (2): 93–100. doi: 10.1212/01.wnl.0000314832.24682.c6.

20. Pena JA, Ravelo ME, Mora-La Cruz E et al. NMO in pediatric patients: brain involvement and clinical expression. Arq Neuropsiquiatr 2011; 69 (1): 34–38. doi: 10.1590/s0004-282x2011000100008.

21. Kim HJ, Paul F, Lana-Peixoto MA et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 2015; 84 (11): 1165–1173. doi: 10.1212/WNL.0000000000001367.

22. Absoud M, Lim MJ, Appleton R et al. Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features. J Neurol Neurosurg Psychiatry 2015; 86 (4): 470–472. doi: 10.1136/jnnp-2014-308550.

23. Hintzen RQ, Dale RC, Neuteboom RF et al. Pediatric acquired CNS demyelinating syndromes: features associated with multiple sclerosis. Neurology 2016; 87 (9 Suppl 2): S67–S73. doi: 10.1212/WNL.0000000000002881.

24. Pohl D, Alper G, Van Haren K, et al. Acute disseminated encephalomyelitis: updates on an inflammatory CNS syndrome. Neurology 2016; 87 (9 Suppl 2): S38–S45. doi: 10.1212/WNL.0000000000002825.

25. Nytrova P, Kleinova P, Preiningerova Lizrova J et al. Neuromyelitis optica a poruchy jejího širšího spectra – retrospektivní analýza klinických a paraklinických nálezů. Cesk Slov Neurol N 2015; 78/111 (1): 72–77. doi: 10.14735/amcsnn201572.

26. Rostasy K, Bajer-Kornek B, Venkateswaran S et al. Differential diagnosis and evaluation in pediatric inflammatory demyelinating disorders. Neurology 2016; 87 (9 Suppl 2): S28–S37. doi: 10.1212/WNL.0000000000002878.

27. Romeo AR, Segal BM. Treatment of neuromyelitis optica spectrum disorders. Curr Opin Rheumatol 2019; 31 (3): 250–255. doi: 10.1097/BOR.0000000000000603.

28. Trebst C, Jarius S, Berthele A et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the neuromyelitis optica study group (NEMOS). J Neurol 2014; 261 (1): 1–16. doi: 10.1007/s00415-013-7169-7.

29. Costanzi C, Matiello M, Lucchinetti CF et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 2011; 77 (7): 659–666. doi: 10.1212/WNL.0b013e31822a2780.

30. Elsone L, Kitley J, Luppe S et al. Long-term efficacy, tolerability, and retention rate of azathioprine in 103 acquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler 2014; 20 (11): 1533–1540. doi: 10.1177/1352458514525870.

31. Jacob A, Matiello M, Weinshenker BG et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009; 66 (9): 1128–1133. doi: 10.1001/archneurol.2009.175.

32. Yang Y, Wang CJ, Wang BJ et al. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder. J Neurol Sci 2018; 385: 192–197. doi: 10.1016/j.jns.2017.12.034.

33. Mahmood NA, Silver K, Onel K. Efficacy and safety of rituximab in pediatric neuromyelitis optica. J Child Neurol 2011; 26 (2): 244–247. doi: 10.1177/0883073810381445.

34. Nosadini M, Alper G, Riney CJ et al. Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm 2016; 3 (1): e188. doi: 10.1212/NXI.0000000000000188.

35. Gao F, Chai B, Gu C et al. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis. BMC Neurol 2019; 19 (1): 36 doi: 10.1186/s12883-019-1261-2.

36. Nikoo Z, Badihian S, Shaygannejad V et al. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol 2017; 264 (9): 2003–2009. doi: 10.1007/s00415-017-8590-0.

37. Yang Y, Wang CJ, Wang BJ et al. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder. J Neurol Sci 2018; 385: 192–197. doi: 10.1016/j.jns.2017.12.034.

38. Hacohen Y, Banwell B. Treatment approaches for MOG-Ab-associated demyelination in children. Curr Treat Options Neurol 2019; 21 (1) : 2. doi: 10.1007/ s11940-019-0541-x

39. Collongues N, Marignier R, Zephir H et al. Long-term follow-up of neuromyelitis optica with a pediatric onset. Neurology 2010; 75 (12) : 1084–1088. doi: 10.1212/ WNL.0b013e3181f39a66.